KLRB1 gene inactivation or antibody-mediated KLRB1 blockade enhances T cell-mediated glioma cell killing in vitro, and the CD161_CLEC2D pathway defines a potential target for immunotherapy of glioma and other human cancers (49). Here, KLRB1 is linked to cancer.